Refine by
Disease Recurrence Articles & Analysis
15 news found
In addition to Guardant SHIELD, clinicians will be able to order current flagship tests such as Guardant360® CDx and Guardant360 Response™ to help physicians inform treatment decisions for patients with advanced cancer, and Guardant Reveal™ to detect residual and recurrent disease in patients with early-stage cancer. This integration will ensure ...
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the enrolment and treatment of the first patient in its multicentre SCIB1 Phase 2 clinical trial at the Churchill Hospital, Oxford University Hospitals Trust, UK. ...
ByScancell
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and year ended December 31, 2021. ...
An interim analysis from COSMOS-CRC-01, a large, prospective, observational study, shows that the Guardant Reveal™ liquid biopsy test, when performed after curative intent surgery for stage II-III colorectal cancer, can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time of greater than six months. ...
” Survival analysis is a game-changer for a diverse variety of disciplines and areas of research Most experts, however, mistakenly consider survival analysis a tool solely applied to study death and disease, an accurate method to measure relapse of a medical condition, the potential hospitalization of a patient, and the mortality rate in medicine and biomedical ...
ByJADBio
High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA exercises $23.8 million option to support ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of a secondary, post-hoc analysis of data from the prospective LOCATE and FALCON clinical trials that evaluated the impact of Axumin® (fluciclovine F 18) PET/CT imaging on management of patients with recurrent ...
Among more than 120 patients’ organizations (branches), a comprehensive breast cancer healthcare eco-system will be set up to care for breast cancer patients, breast cancer survivors and help their families to hopefully eliminate the fear of succumbing to the disease or possible recurrences and minimize associated social and financial challenges to their ...
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx ...
-Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test. ...
Such interruption in NMIBC follow-up greatly increases the risk for undetected tumor recurrence, and for these patients, missed or avoided monitoring visits could mean the difference between early treatment and critical disease progression. ...
IORT using the Zeiss® Intrabeam® System has been proven to be non-inferior to External Beam Radiation Therapy (EBRT) in local recurrence and disease-free survival. IORT’s advantage is one treatment during surgery instead of several weeks of EBRT which has obvious benefits for patient convenience, compliance and quality of life. ...
Notes to editorsAbout Clostridioides difficile infection (C. diff) C. diff is a bacterium that causes diarrhea and colitis (an inflammation of the colon).6 It is estimated to cause up to half a million illnesses in the US alone every year and is considered an urgent threat to public health by the CDC, and can lead to severe complications, including hospitalization, surgery, and death.2 While ...
"These advantages undoubtedly will speed the drug's availability for a disease that kills hundreds of thousands of patients annually world-wide." While hepatocellular carcinoma afflicts 54,000 patients a year in the US (Cancer.net), the World Health Organization estimates the disease causes as many as 880,000 deaths per year globally–especially in China ...
This capability may also enable longitudinal monitoring of potential disease recurrence, may identify therapy escape mechanisms and resistance growth pathways, and thereby support accelerated new drug development. ...